Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Status:
Completed
Trial end date:
2019-10-09
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the cancer.
PURPOSE: This phase II trial is studying the side effects and how well everolimus works in
treating patients with lymphoma that has relapsed or not responded to previous treatment.